Compare Stocks

→ What is Medicare Supplement Insurance? (From Tranzact) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALT Altimmune	$7.20 +1.7%	$9.31	$2.09 ▼ $14.84	$501.94M	0.05	5.35 million shs	2.31 million shs
AMT American Tower	$172.96 -0.2%	$190.60	$154.58 ▼ $219.10	$80.66B	0.67	2.43 million shs	1.86 million shs
ORTH Ortho Regenerative Technologies		$0.00	$0.37 ▼ $1.00	N/A	N/A	N/A	2,500 shs

These 7 Stocks Will Be Magnificent in 2024

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALT Altimmune	-6.47%	+0.57%	-17.00%	-23.71%	+35.37%
AMT American Tower	-0.49%	+0.77%	-11.36%	-13.45%	-14.07%
ORTH Ortho Regenerative Technologies	0.00%	0.00%	0.00%	0.00%	0.00%

The Best AI Stock to Own in the World Today is Trading for Just $25 (Ad)

“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.

See how you can invest alongside him

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALT Altimmune	1.3757 of 5 stars	3.3	1.0	0.0	0.0	3.2	1.7	0.0
AMT American Tower	4.983 of 5 stars	4.4	5.0	2.5	3.1	2.7	2.5	1.9
ORTH Ortho Regenerative Technologies	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALT Altimmune	2.67	Moderate Buy	$15.00	108.33% Upside
AMT American Tower	2.82	Moderate Buy	$217.36	25.67% Upside
ORTH Ortho Regenerative Technologies	N/A	N/A	N/A	N/A

Current Analyst Ratings

Latest ORTH, ADR, AMT, and ALT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/15/2024	AMT American Tower	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$183.00 ➝ $196.00
4/8/2024	AMT American Tower	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Neutral	$205.00
4/1/2024	ALT Altimmune	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$15.00 ➝ $12.00
3/28/2024	ALT Altimmune	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00
3/5/2024	AMT American Tower	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$224.00 ➝ $234.00
2/28/2024	AMT American Tower	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$235.00 ➝ $228.00
2/28/2024	AMT American Tower	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$236.00 ➝ $230.00
2/13/2024	ALT Altimmune	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00

(Data available from 4/25/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALT Altimmune	$426K	1,198.23	N/A	N/A	$2.75 per share	2.62
AMT American Tower	$11.14B	7.24	$9.84 per share	17.58	$23.30 per share	7.42
ORTH Ortho Regenerative Technologies	N/A	N/A	N/A	N/A	N/A	N/A

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALT Altimmune	-$88.45M	-$1.65	N/A	N/A	N/A	-20,780.75%	-44.77%	-40.72%	5/9/2024 (Estimated)
AMT American Tower	$1.48B	$3.18	54.39	16.76	1.38	13.31%	12.80%	2.24%	4/30/2024 (Confirmed)
ORTH Ortho Regenerative Technologies	N/A	N/A	0.00	N/A	N/A	N/A	N/A	N/A	N/A

Latest ORTH, ADR, AMT, and ALT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
4/30/2024	N/A	AMT American Tower	$2.45	N/A	-$2.45	N/A	N/A	N/A
3/27/2024	Q4 2023	ALT Altimmune	-$0.35	-$0.33	+$0.02	-$0.12	N/A	$0.04 million
2/27/2024	12/31/2023	AMT American Tower	$2.10	$0.94	-$1.16	$0.18	$2.74 billion	$2.79 billion

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALT Altimmune	N/A	N/A	N/A	N/A	N/A
AMT American Tower	$6.48	3.75%	+12.50%	203.77%	N/A
ORTH Ortho Regenerative Technologies	N/A	N/A	N/A	N/A	N/A

Latest ORTH, ADR, AMT, and ALT Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
3/14/2024	AMT American Tower	quarterly	$1.62	3.3%	4/11/2024	4/12/2024	4/26/2024

(Data available from 1/1/2013 forward)

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALT Altimmune	N/A	17.26	17.26
AMT American Tower	3.29	0.69	0.69
ORTH Ortho Regenerative Technologies	N/A	N/A	N/A

Ownership

Institutional Ownership

Company	Institutional Ownership
ALT Altimmune	78.05%
AMT American Tower	92.69%
ORTH Ortho Regenerative Technologies	N/A

Insider Ownership

Company	Insider Ownership
ALT Altimmune	4.10%
AMT American Tower	0.24%
ORTH Ortho Regenerative Technologies	N/A

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
ALT Altimmune	59	70.90 million	67.99 million	Optionable
AMT American Tower	5,643	466.35 million	465.23 million	Optionable
ORTH Ortho Regenerative Technologies	N/A	N/A	N/A	Not Optionable

ORTH, ADR, AMT, and ALT Headlines

Source	Headline
	Orthopedic Institute of Pennsylvania opens ASC beckersasc.com - April 24 at 8:20 PM
	LSU researchers develop syringe device for enhanced stem cell therapy lsureveille.com - April 24 at 9:44 AM
	The medtech giants dominating orthopedics beckersspine.com - April 22 at 2:41 PM
	Rising Prevalence of Orthopedic Disorders among Aging Population is Driving the Demand for Advanced Bone Screw Systems \| Future Market Insights, Inc. finance.yahoo.com - April 22 at 9:41 AM
	Cherokee Nation hosts ARPA-H’s novel osteoarthritis regeneration program cherokeephoenix.org - April 20 at 4:40 PM
	$33 Million to Truly Regenerate Arthritic Joints ryortho.com - April 19 at 12:41 PM
	4 recent orthopedic surgery firsts beckersspine.com - April 18 at 9:02 PM
	Bone Grafts and Substitutes Market Size and Scope, Industry snapshot, Leading Companies and Opportunity Analysis by 2032 taiwannews.com.tw - April 17 at 2:05 PM
	Medical Collagen Market Overview, Latest Trends, Key Players, Revenue, and Forecast 2024 to 2032 taiwannews.com.tw - April 17 at 9:05 AM
	Unlocking the Transformative Potential of Bioactive Glass in Healthcare msn.com - April 16 at 10:05 AM
	How orthopedic surgeon pay compares to 14 other specialties beckersspine.com - April 15 at 7:16 PM
	Aligned Orthopedic Partners taps new CEO beckersspine.com - April 15 at 2:15 PM
	Table of Experts: Advancements in orthopedic care bizjournals.com - April 12 at 8:20 AM
	OrthoLite Expands Patent Protection for its Hybrid Technology Line sgbonline.com - April 10 at 5:47 PM
	Achy joints? Duke researchers get grant for regeneration thecharlottepost.com - April 10 at 12:46 PM
	4 systems acquiring orthopedic, spine groups in 4 months beckersspine.com - April 10 at 7:37 AM
	7 top hospitals for both spine and orthopedic research beckersspine.com - April 8 at 8:24 PM
	Rational Design of Nanofiber Scaffolds for Orthopedic Tissue Repair and Regeneration medscape.com - April 6 at 10:33 AM
	RIT faculty member becomes fellow of the American Institute for Medical and Biological Engineering rit.edu - April 1 at 8:42 PM
	Knight Campus director Bob Guldberg to speak at TEDxPortland around.uoregon.edu - April 1 at 10:41 AM
	Bone Growth Stimulators Market Exploring the Unseen The Next Frontier of Deep Understanding through Observation taiwannews.com.tw - April 1 at 10:41 AM
	'Private equity has the potential to be very beneficial': What we heard in March beckersspine.com - March 29 at 6:01 PM
	J&J’s Aldo Denti on digital technology in orthopedics medtechdive.com - March 29 at 1:01 PM
	Duke leads $33M federal project to forward osteoarthritis treatment, rebuild joints bizjournals.com - March 27 at 7:46 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

This Underrated Natural Gas Stock Could Rally Double-Digits Soon
April 1, 2024 9:15 AM
View This Underrated Natural Gas Stock Could Rally Double-Digits Soon
Low Interest Rates Can Help These Commercial Banks Rally Higher
April 2, 2024 11:38 AM
View Low Interest Rates Can Help These Commercial Banks Rally Higher
Is DraftKings A Good Bet Ahead of Q1 Earnings?
March 27, 2024 10:45 AM
View Is DraftKings A Good Bet Ahead of Q1 Earnings?
3M Spun Off Its Health Division, Is It Still A Buy?
April 4, 2024 7:47 AM
View 3M Spun Off Its Health Division, Is It Still A Buy?
PriceSmart Could Be the Smartest Buy of the Year
April 11, 2024 7:35 AM
View PriceSmart Could Be the Smartest Buy of the Year

All Headlines

Company Descriptions

Altimmune

NASDAQ:ALT

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.

American Tower

NYSE:AMT

American Tower, one of the largest global REITs, is a leading independent owner, operator and developer of multitenant communications real estate with a portfolio of over 224,000 communications sites and a highly interconnected footprint of U.S. data center facilities.

Ortho Regenerative Technologies

CNSX:ORTH

Ortho Regenerative Technologies Inc., an orthopedic and sports medicine technology company, engages in researching and developing novel therapeutic tissue repair devices to enhance the success rate of sports medicine surgeries in Canada. The company develops Ortho-R, a freeze-dried formulation for the treatment of rotator cuff tears; and Ortho-M, a freeze-dried formulation for the treatment of meniscus tears that are under the large animal studies. It also develops Ortho-C, a freeze-dried matrix for the treatment of articular cartilage; and Ortho-V, a freeze-dried biopolymer for the prevention of osteoarthritis pain that are under the feasibility studies. The company was incorporated in 2015 and is headquartered in Kirkland, Canada.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial